Enhanced risk for recurrent adverse cardiovascular events in homozygous carriers of the T-allele of CD40 SNP rs1883832 [0.03%]
CD40基因SNP rs1883832位点TT纯合子携带者反复发生不良心血管事件的风险增加
Mark Colin Gissler,Johannes Neumann,Linlin Guo et al.
Mark Colin Gissler et al.
Background and aims: The co-stimulatory signaling dyad of CD40 and CD40L is a potent inducer of cardiovascular inflammation and vulnerability of atherosclerotic plaques. A cytosine-to-thymidine transition (-1C > T) in the...
Karin Littmann,Daniel Eriksson Hogling,Mustafa Suhel et al.
Karin Littmann et al.
Background and aim: Elevated lipoprotein(a) [Lp(a)] contributes to coronary artery disease (CAD). This study aimed to determine the effectiveness of cascade screening for elevated Lp(a) in patients with CAD. ...
Lipoprotein(a), interleukin-6 and cardiovascular risk in a primary prevention setting [0.03%]
基于初级预防的载脂蛋白(a)、白介素-6和心血管风险关系研究
Johan Skov Bundgaard,Søren Albertsen Rand,Stefan Stender et al.
Johan Skov Bundgaard et al.
Background and aim: Both lipoprotein(a) [Lp(a)] and inflammation are independent causal risk factors for atherosclerotic cardiovascular disease (ASCVD). While previous studies have indicated that subclinical inflammation ...
Correspondence on: Impact of coronary artery disease patterns assessed with pullback pressure gradient on clinical outcomes: Meta-analysis [0.03%]
关于冠状动脉疾病模式与临床结局的通信:Meta分析
Artur Dziewierz,Barbara Zdzierak,Stanisław Bartuś et al.
Artur Dziewierz et al.
Corrigendum to "Characterization of lipoprotein (a) testing in Alberta, Canada: a retrospective cohort study" [Atherosclerosis 408, (2025) 120458] [0.03%]
“脂蛋白(a)检测在加拿大阿尔伯塔省的特征：一项回顾性队列研究”的勘误(动脉粥样硬化第408卷120458号，2025年发表)
Phongsack Manivong,Eileen Shaw,Tram Pham et al.
Phongsack Manivong et al.
Published Erratum
Atherosclerosis. 2026 Apr 27:417:120606. DOI:10.1016/j.atherosclerosis.2025.120606 2026
Preoperative proprotein convertase subtilisin/kexin type 9 inhibitors versus statins and postoperative adverse events in hyperlipidemia: A nationwide, active-comparator cohort study [0.03%]
前蛋白转化酶枯草杆菌肽/kexin 9抑制剂与他汀类药物在高脂血症术后的不良事件：一项全国性、主动对照队列研究
Hsiang-Ling Wu,Jui-Tai Chen,Juan Pablo Cata et al.
Hsiang-Ling Wu et al.
Background and aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors achieve substantial reductions in low-density lipoprotein cholesterol, yet their effectiveness and safety in the perioperative setting ...
Common and distinct genetic features of three atherosclerotic cardiovascular diseases [0.03%]
三种动脉粥样硬化性心血管疾病的共有和特有遗传特征
Ling Li,Rainer Malik,Carla Abrahamian et al.
Ling Li et al.
Background and aims: Coronary artery disease (CAD), peripheral arterial disease (PAD), and ischemic stroke (IS) are the principal manifestations of atherosclerotic cardiovascular diseases (ASCVDs). Here we systematically ...
Association of the residual SYNTAX score on clinical outcomes in patients with acute coronary syndrome [0.03%]
SYNTAX评分对急性冠脉综合征患者的临床预后的影响研究
Taito Arai,Koshiro Sakai,Hiroyoshi Mori et al.
Taito Arai et al.
Background: The residual SYNTAX score (rSS) quantifies coronary artery disease extent following percutaneous coronary intervention (PCI) and predicts adverse outcomes. However, its relationship with plaque morphology in a...
Long-term trends in dyslipidemia prevalence, awareness, treatment, and control in the Middle East and North Africa: a meta-analysis of 116 representative surveys [0.03%]
Meta分析：评估中东和北非地区血脂异常患病率、知晓率、治疗率及控制率的长期变化趋势（基于116项横断面调查数据）
Ehsaneh Taheri,Shirin Esmaeili,Saeed Hamidizadeh et al.
Ehsaneh Taheri et al.
Background and aims: Dyslipidemia is a major risk factor for cardiovascular disease. Trends in dyslipidemia prevalence have been poorly described in the Middle East and North Africa region (MENA). We evaluated the prevale...
Yasushi Ueki,Sylvain Losdat,Konstantinos C Koskinas et al.
Yasushi Ueki et al.